Duvelisib
- Generic Name
- Duvelisib
- Brand Names
- Copiktra
- Drug Type
- Small Molecule
- Chemical Formula
- C22H17ClN6O
- CAS Number
- 1201438-56-3
- Unique Ingredient Identifier
- 610V23S0JI
- Background
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of bo...
- Indication
Duvelisib is indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients who have trialed at least two prior therapies.
- Associated Conditions
- Refractory Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Small Lymphocytic Lymphoma
- Associated Therapies
- -
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04707079
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, Shanghai, China
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 13
- Registration Number
- NCT04688658
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 38
- Registration Number
- NCT04652960
- Locations
- 🇺🇸
Siteman Cancer Center-South County, Saint Louis, Missouri, United States
🇺🇸Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States
🇺🇸Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04639843
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Emory University
- Target Recruit Count
- 47
- Registration Number
- NCT04487886
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
Duvelisib to Combat COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 28
- Registration Number
- NCT04372602
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- SecuraBio
- Target Recruit Count
- 2
- Registration Number
- NCT04342117
- Locations
- 🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States
🇺🇸Joliet Oncology-Hematology Associates, LTD, Joliet, Illinois, United States
🇺🇸McFarland Clinic,PC, Ames, Iowa, United States
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 17
- Registration Number
- NCT04331119
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2022-03-09
- Target Recruit Count
- 3
- Registration Number
- NCT04209621
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- SecuraBio
- Target Recruit Count
- 2
- Registration Number
- NCT04193293
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.